Regenicin values The Asset Purchase Agreement tran
Post# of 99
Posted On: 03/16/2015 9:35:14 AM
Regenicin values The Asset Purchase Agreement transaction with Amarantus at $8.023 million, comprised of $3.075 million in cash, $3.0 million in Amarantus restricted stock, and payments and forgiveness of liabilities and notes totaling, $1.948 million. It should be noted that the Amarantus stock is restricted from sale until May 7, 2015.
Management believes that this transaction will provide Regenicin adequate funding to continue product development of life saving technology. It is estimated that the proceeds should bring us to the initiation of FDA sanctioned clinical trials with our first cell therapy wound care product.
"We are excited to have the Asset Purchase Agreement completed," says Randall McCoy CEO of Regenicin. "We are now well positioned to establish Regenicin's own cell therapy product in the FDA approval pipeline."
Management believes that this transaction will provide Regenicin adequate funding to continue product development of life saving technology. It is estimated that the proceeds should bring us to the initiation of FDA sanctioned clinical trials with our first cell therapy wound care product.
"We are excited to have the Asset Purchase Agreement completed," says Randall McCoy CEO of Regenicin. "We are now well positioned to establish Regenicin's own cell therapy product in the FDA approval pipeline."
(0)
(0)Regenicin Inc. (RGIN) Stock Research Links
Scroll down for more posts ▼